AUSTIN, TX and TORONTO, ON, Nov. 12, 2013 /PRNewswire/ - Affinium
Pharmaceuticals ("Affinium") announced today that the U.S. Food and
Drug Administration (FDA) has designated Affinium's Phase 2 antibiotic,
AFN-1252, as a Qualified Infectious Disease Product (QIDP) for use in
acute......
More...
